Systematic evaluation of multiple qPCR platforms, NanoString and miRNA-Seq for microRNA biomarker discovery in human biofluids.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Biomarkers/*metabolism ; Body Fluids/*metabolism ; Circulating MicroRNA/*genetics ; Nanotechnology/*methods ; Real-Time Polymerase Chain Reaction/*methods; Cell Line ; Gene Expression Profiling/methods ; Genetic Techniques ; HEK293 Cells ; Humans ; THP-1 Cells

Aberrant miRNA expression has been associated with many diseases, and extracellular miRNAs that circulate in the bloodstream are remarkably stable. Recently, there has been growing interest in identifying cell-free circulating miRNAs that can serve as non-invasive biomarkers for early detection of disease or selection of treatment options. However, quantifying miRNA levels in biofluids is technically challenging due to their low abundance. Using reference samples, we performed a cross-platform evaluation in which miRNA profiling was performed on four different qPCR platforms (MiRXES, Qiagen, Applied Biosystems, Exiqon), nCounter technology (NanoString), and miRNA-Seq. Overall, our results suggest that using miRNA-Seq for discovery and targeted qPCR for validation is a rational strategy for miRNA biomarker development in clinical samples that involve limited amounts of biofluids.

BMC Genomics. 2019 Jun 3;20(1):446. (PMID: 31159762)
BMC Genomics. 2018 May 5;19(1):331. (PMID: 29728066)
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8. (PMID: 21383194)
Nat Biotechnol. 2018 Sep;36(8):746-757. (PMID: 30010675)
Nat Rev Clin Oncol. 2011 Jun 07;8(8):467-77. (PMID: 21647195)
PLoS One. 2015 Mar 26;10(3):e0121521. (PMID: 25812157)
Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):25036-25042. (PMID: 32943537)
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8. (PMID: 18663219)
Clin Chem. 2019 Sep;65(9):1132-1140. (PMID: 31235535)
Biometrics. 1989 Mar;45(1):255-68. (PMID: 2720055)
Front Genet. 2011 Feb 28;2:7. (PMID: 22303306)
Microrna. 2020;9(1):17-24. (PMID: 31264553)
Oncotarget. 2018 Mar 30;9(24):16691-16700. (PMID: 29682178)
Nat Rev Clin Oncol. 2014 Mar;11(3):145-56. (PMID: 24492836)
J Am Coll Cardiol. 2019 Mar 26;73(11):1300-1313. (PMID: 30898206)
Front Pharmacol. 2020 Jan 20;10:1500. (PMID: 32038230)
Nat Methods. 2014 Aug;11(8):809-15. (PMID: 24973947)
Front Immunol. 2017 Mar 24;8:308. (PMID: 28392786)
Gut. 2020 Oct 7;:. (PMID: 33028667)
Front Genet. 2015 Dec 22;6:352. (PMID: 26734062)
Nucleic Acids Res. 2012 Jan;40(1):37-52. (PMID: 21911355)
Nat Rev Genet. 2012 Apr 18;13(5):358-69. (PMID: 22510765)
Nat Rev Mol Cell Biol. 2005 May;6(5):376-85. (PMID: 15852042)
J Allergy Clin Immunol. 2018 Apr;141(4):1202-1207. (PMID: 29074454)
Science. 2001 Oct 26;294(5543):853-8. (PMID: 11679670)
Dev Cell. 2006 Oct;11(4):441-50. (PMID: 17011485)
Nat Commun. 2017 Sep 21;8(1):653. (PMID: 28935855)
Mol Oncol. 2013 Jun;7(3):334-45. (PMID: 23177026)
Nat Rev Genet. 2010 Sep;11(9):597-610. (PMID: 20661255)
Expert Rev Mol Diagn. 2019 Jul;19(7):579-590. (PMID: 31215265)
BMC Genomics. 2018 Feb 5;19(1):118. (PMID: 29402217)
J Cell Mol Med. 2020 Oct;24(20):12054-12064. (PMID: 32916773)
Br J Cancer. 2018 Mar 20;118(6):857-866. (PMID: 29360813)
PLoS One. 2017 Dec 6;12(12):e0189165. (PMID: 29211799)
Biomark Med. 2017 Jan;11(1):69-86. (PMID: 27917642)
Front Physiol. 2019 Apr 05;10:379. (PMID: 31024340)
Cell. 2009 Jan 23;136(2):215-33. (PMID: 19167326)
Front Genet. 2013 May 16;4:83. (PMID: 23720669)
Stem Cells. 2010 Oct;28(10):1893-904. (PMID: 20715183)
Int J Biochem Cell Biol. 2010 Aug;42(8):1256-61. (PMID: 20144731)
BMC Genomics. 2014 Jun 03;15:423. (PMID: 24894665)

0 (Biomarkers)
0 (Circulating MicroRNA)

Date Created: 20210225 Date Completed: 20211214 Latest Revision: 20211214

20221213

PMC7904811

10.1038/s41598-021-83365-z

33627690